Abiopharma

CARDLYTICS, INC. (CDLX)

Symbol	CDLX
Name	CARDLYTICS, INC.
Sector	TECHNOLOGY
Region	North America
Industry	Computer Software: Programming, Data Processing
Address	675 PONCE DE LEON AVENUE NE,SUITE 4100, ATLANTA, Georgia, 30308, United States
Telephone	+1 888 - 798-5802
Fax	—
Email	—
Website	https://www.cardlytics.com
Incorporation	UNDEFINED
Incorporated On	—
Employees	—
Fiscal Year	—
Public Since	—
Exchanges	NASDAQ
Auditor	—
Audit Status	NOT PROVIDED
Reporting Status	—
CIK	0001666071
Description	Cardlytics Inc operates an advertising platform within financial institutions digital channels, which include online, mobile, email and various real-time notifications. The company operates through three segments, Cardlytics Direct U.S. and U.K., and Bridg platform. The Cardlytics Direct segment which generates majority revenue operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to our cloud-based customer-data platform and the delivery of professional services like implementation, onboarding and technical support. Geographically the company receives maximum revenue from the United States. Additional info from NASDAQ: Cardlytics Inc operates an advertising platform within financial institutions digital channels, which include online, mobile, email and various real-time notifications. The company operates through three segments, Cardlytics Direct U.S. and U.K., and Bridg platform. The Cardlytics Direct segment which generates majority revenue operates a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. The Bridg platform generates revenue through the sale of subscriptions to our cloud-based customer-data platform and the delivery of professional services like implementation, onboarding and technical support. Geographically the company receives maximum revenue from the United States.

2026-08-18 21:27

Director Gupta Amit 🟡 adjusted position in 13.5K shares (2 derivative) of Cardlytics, Inc. (CDLX) at $4.03 Transaction Date: Aug 16, 2026 | Filing ID: 057772

2026-08-18 21:15

📋 Gupta Amit (Officer) plans to sell 7K shares of Cardlytics, Inc. (at $4.03 each, total $27K) Filed: Aug 18, 2026 | ID: 006193

2026-08-17 19:38

📋 Gupta Amit (Officer) plans to sell 7K shares of Cardlytics, Inc. (at $3.97 each, total $27K) Filed: Aug 17, 2026 | ID: 006109

2026-08-05 20:01

Cardlytics Second Quarter 2026 Financial Results Driven By Strong Operational Performance

2026-08-03 20:07

Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-31 12:30

Cardlytics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

2026-07-29 12:30

Cardlytics Appoints Chris Cheng as Chief Legal Officer

2026-07-21 12:30

Cardlytics to Report Second Quarter 2026 Results on August 5

2026-07-06 21:52

Director Gupta Amit 🟡 adjusted position in 16.1K shares (2 derivative) of Cardlytics, Inc. (CDLX) at $4.39 Transaction Date: Jul 01, 2026 | Filing ID: 047392

2026-07-06 21:39

Lynton Nicholas Hollmeyer 🟡 adjusted position in 2.2K shares (4 derivative) of Cardlytics, Inc. (CDLX) at $4.39 Transaction Date: Jul 01, 2026 | Filing ID: 047389